PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series
DOI: https://doi.org/10.2147/idr.s441460
2024-04-19
Infection and Drug Resistance
Abstract:LeiLei Chen, Jingshi Wang, Zhao Wang Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Zhao Wang, Capital Medical University, Beijing, People's Republic of China, Email Hemophagocytic lymphohistiocytosis (HLH), whether primary or secondary, is a rare and fatal clinical syndrome of uncontrolled immune activation and inflammatory cascade. Immune checkpoint inhibitors (ICIs) induced HLH has no standard diagnostic and treatment guidelines. Early diagnosis and appropriate treatment according to different disease backgrounds are crucial. Herein, we first report 2 cases of patients with chronic active Epstein-Barr virus infection (CAEBV) who developed HLH after the use of sintilimab, a monoclonal antibody against programmed cell death protein 1 (PD-1), and the DEP (liposomal doxorubicin, etoposide, methylprednisolone) chemotherapy regimen in combination with ruxolitinib were used to successfully control the disease. Keywords: PD-1 blockade, hemophagocytic lymphohistiocytosis, CAEBV, case report case series Hemophagocytic lymphohistiocytosis is a syndrome of excessive inflammation and tissue destruction due to abnormal immune activation. The immunological abnormalities are thought to result from the absence of normal downregulation driven by activated macrophages and lymphocytes. In HLH, natural killer cells and cytotoxic lymphocytes fail to eliminate activated macrophages. This lack of normal feedback regulation results in activation of CD8+ T cells and macrophages activation with highly elevated levels of interferon gamma (IFN-γ) and other cytokines that drive the pathology of HLH. HLH occurs either as primary HLH or as acquired HLH. Both terms can be triggered by infection or other immune-activating events. 1,2 Currently, programmed cell death receptor 1 (PD-1) blockade has been widely used in numerous solid tumors and refractory/relapsed Hodgkin lymphoma, and has expanded the treatment landscape of these tumors due to its efficacy. There are now several reports of CAEBV being successfully treated with PD-1 blockade. 3,4 PD-1 blockade can bind to PD-1, preventing it from binding to programmed death ligands 1 (PD-L1) and 2 (PD-L2), and restoring CD8+ T cells function. 5 However, persistent off-target activation of CD8+ T cells can lead to multi-organ failure as immune-related adverse events (irAEs) or ultimately induce HLH. 6 Nevertheless, cases of immunotherapy-induced HLH triggered by immunotherapy in CAEBV patients are rarely reported. In this report, we present 2 cases of CAEBV patients diagnosed with HLH induced by sintilimab during immunotherapy. The disease was completely controlled by initiation of DEP chemotherapy regimen combined with ruxolitinib after appropriate and timely diagnosis. A 35-year-old man with a 1-year history of intermittent fever was admitted to our center on 19 January 2021. Approximately 1 year before, the patient was admitted to a local hospital for intermittent fever. Abdominal ultrasound showed splenomegaly. Laboratory tests showed an EBV-DNA loads of 1.0E+06 copies/mL in peripheral blood mononuclear cells (PBMC). He was treated with dexamethasone at the local hospital without improvement. On admission, his vital signs were normal with an unremarkable physical examination except for inguinal lymphadenoma and splenomegaly. Initial workup revealed the EBV-DNA loads in plasma and PBMC of 1.9E+04 copies/mL and 3.3E+06 copies/mL, respectively. Lymphocyte subgroups of EBV infection showed CD3+CD4+ cells 3.6E+04 copies/mL, CD3+CD8+ cells 0, CD3-CD19+ cells 0, CD56+ cells 7.4E+05 copies/mL. Histopathological examination of the left inguinal lymph nodes revealed EBV-positive T cell proliferation disease (stage 1) (EBV + T-LPD 1). An initial complete blood count revealed a white blood cell (WBC) count of 2.99*10 9 /L, a neutrophil granulocyte (GR) count of 1.96*10 9 /L, a hemoglobin (Hb) count of 120 g/L, and a platelet (PLT) count of 149*10 9 /L. The results of the biochemical tests were as follows; alanine aminotransferase (ALT) 37 U/L (normal; 9–50 U/L), aspartate aminotransferase (AST) 36 U/L (normal; 58–40 U/L), total bilirubin (TBIL) 13.9 umol/L (normal; 3.4–17.1 umol/L), and lactate dehydrogenase (LDH) 248 U/L (normal; 120–250 U/L). Whole exome sequencing (WES) revealed no immunodeficiency mutations, and positron emission tomography/computed tomography (PET/CT) showed no enlarged and hypermetabolic lesions except for inguinal lymph nodes, and the bone marrow biopsy showed no evidence of lymphoma. This patient was diagnosed with CAEBV based on the history of fever, lymphadenoma, splenomegaly, laboratory findings and lymph nodes biopsy pathology. He was registered to receive sintilimab (Suchow Xinda Biotechnology Co.; -Abstract Truncated-
pharmacology & pharmacy,infectious diseases